Brief: Candel Therapeutics Reports First Quarter 2023 Financial Results
11/05/2023 14:00
May 11 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND RECENT CORPORATE HIGHLIGHTS
* CANDEL THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF
MARCH
31, 2023 WERE $59.3 MILLION
* CANDEL THERAPEUTICS INC - EXPECTS EXISTING CASH AND CASH
EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATING
PLAN INTO H2 2024
Source text for Eikon: ID:nGNXbYnzSG
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec